Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats

Obesity

Volumn 19, Issue 7, 2011, Pages 1342-1349

  Hayes, Matthew R ^a   Kanoski, Scott E ^a   Alhadeff, Amber L ^a   Grill, Harvey J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; LIRAGLUTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FOOD INTAKE; LIPID DIET; MALE; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; RAT; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE REGULATION; DIETARY FATS; DIETARY SUCROSE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; LIGANDS; MALE; OBESITY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; TIME FACTORS; VENOMS; WEIGHT LOSS;

RATTUS;

EID: 79959675075     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.50     Document Type: Article

References (34)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157. (Pubitemid 46711096)
2. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269.
3. Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 2010;100:503-510.
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439. (Pubitemid 350041474)
5. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010;9:267-268.
6. Buse JB, Rosenstock J, Sesti G et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
7. Astrup A, Rössner S, Van Gaal L et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616.
8. Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition 2010;26:243-249.
9. Madsen AN, Hansen G, Paulsen SJ et al. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol 2010;206:287-296.
10. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009;150:1174-1181.
11. Thum T, Anker SD. Liraglutide for weight loss in obese people. Lancet 2010;375:551-552; author reply 552.
12. Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007;293:R983-R987. (Pubitemid 47358916)
13. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202. (Pubitemid 34208381)
14. Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagonlike peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-1669. (Pubitemid 30304999)
15. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38:1944-1953.
16. Kapitza C, Zdravkovic M, Zijlstra E et al. Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide. J Clin Pharmacol 2010.
17. Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-1610. (Pubitemid 46871185)
18. Parkes D, Jodka C, Smith P et al. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Develop Res 2001;53:260-267. (Pubitemid 33029654)
19. Pohl M, Wank SA. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem 1998;273:9778-9784. (Pubitemid 28183071)
20. Gedulin BR, Smith PA, Jodka CM et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 2008;356:231-238.
21. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530-2539. (Pubitemid 33642771)
22. Madsen AN, Hansen G, Paulsen S, et al. Long-term characterization of the diet-induced obese and diet resistant rat model: A polygenetic rat model mimicking the human obesity syndrome. J Endocrinol 2010;206:287-296.
23. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103: 687-694.
24. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447. (Pubitemid 44349236)
25. Rosenstock J, Klaff LJ, Schwartz S et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33: 1173-1175.
26. Raun K, von Voss P, Gotfredsen CF et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007;56:8-15.
27. Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008;149:4059-4068.
28. Yamamoto H, Lee CE, Marcus JN et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52. (Pubitemid 34743464)
29. Watson E, Jonker DM, Jacobsen LV, Ingwersen SH. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol 2010;50: 886-894.
30. Burguera B, Couce ME, Curran GL et al. Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. Diabetes 2000;49:1219-1223. (Pubitemid 30439098)
31. Caro JF, Kolaczynski JW, Nyce MR et al. Decreased cerebrospinal-fluid/ serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996;348:159-161. (Pubitemid 26238099)
32. Knight ZA, Hannan KS, Greenberg ML, Friedman JM. Hyperleptinemia is required for the development of leptin resistance. PLoS ONE 2010;5:e11376.
33. Covasa M, Marcuson JK, Ritter RC. Diminished satiation in rats exposed to elevated levels of endogenous or exogenous cholecystokinin. Am J Physiol Regul Integr Comp Physiol 2001;280:R331-R337.
34. Savastano DM, Covasa M. Adaptation to a high-fat diet leads to hyperphagia and diminished sensitivity to cholecystokinin in rats. J Nutr 2005;135:1953-1959. (Pubitemid 41099755)